

Date and Time: 3rd April 2012, 10:30-16:30

Minutes: Confirmed

Hepatitis B GDG Meeting 6

Place: NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ

Present: GDG

1. Howard Thomas (Chair)	HT
2. Elizabeth Boxall	EB
3. Javier Vilar	JV
4. Angela Narbey	AN
5. Geoffrey Dusheiko	GD
6. Aftab Ala	AA
7. Alan Mitchell	AM
8. Gareth Tudor-Williams	GTW
9. Emily Lam	EL
10. Joyeta Das	JD
11. Sarah Wise	SW

NCGC Technical team

12. Gill Ritchie	GR
13. Grammati Sarri	GS
14. Rosa Lau	RL
15. Sarah Bermingham	SB

NICE

16. Sarah Dunsdon	SD
-------------------	----

Apologies

17. Grant Hill-Cawthorne	GHC
18. Amy Kelsey	AK

Notes

1. The Chair welcomed everyone to the Hepatitis B Guideline Development Group (GDG) meeting 6. Apologies were received from Grant Hill-Cawthorne and Amy Kelsey. The Chair welcomed Sarah Wise to the group. Sarah is from the British Liver Trust and joined the GDG as a patient/carer representative.
2. The Chair asked the GDG to declare if they had any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests to declare since their previous declaration (upon acceptance of their GDG role). No one declared any new conflicts of interest.
3. The Chair then briefed the group on the meetings objectives.
4. The Chair introduced Grammati Sarri, NCGC Senior Research Fellow who gave a presentation on the Network Meta Analysis. The Chair thanked GS for her presentation.
5. GS then gave a presentation on the clinical effectiveness of whether genotyping enabled better decisions on which antiviral treatment to offer in patients with CHB. The GDG then discussed the evidence presented. The Chair thanked GS for her presentation.
6. The Chair then introduced Sarah Bermingham, NCGC Acting Senior Health Economist, who gave a presentation on the cost effectiveness of whether genotyping enabled better decisions on which antiviral treatment to offer. The Chair thanked SB for her presentation.
7. The GDG then discussed the evidence presented and drafted recommendations.
8. The Chair then introduced Rosa Lau, NCGC Research Fellow, who gave a presentation on the diagnostic accuracy of non-invasive methods to assess severity of necro-inflammatory activity and liver fibrosis. The GDG then discussed the evidence presented. The Chair thanked RL for her presentation.
9. SB then gave a presentation on the cost effectiveness of the diagnostic accuracy of non-invasive methods to assess severity of necro-inflammatory activity and liver fibrosis. The Chair thanked SB for her presentation.
10. The GDG then discussed the evidence presented and drafted recommendations.
11. SB then gave a presentation on the cost effectiveness of different sequences of antiviral drugs for the treatment of CHB health economic model. The GDG discussed the model. The Chair thanked SB for her presentation.
12. GS and RL then led discussion with the GDG on the research protocol for 2 clinical questions. The protocols for frequency of surveillance testing and prophylactic treatment in people who are immunocompromised were agreed and signed off by the GDG.
13. There was no other business to discuss. The Chair closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

14. Tuesday 8th May 2012, 10:30-16:30, NCGC Boardroom, 180 Great Portland Street, London, W1W 5QZ.